Architectural Heterogeneity in Tumors Caused by Differentiation Alters Intratumoral Drug Distribution and Affects Therapeutic Synergy of Antiangiogenic Organoselenium Compound

Figure 5

Response to cytotoxic drugs alone and in combination with MSC in H69 lung xenografts when treatment was started at ~100 mm³ tumor volume (a), at ~1000 mm³ tumor volume (b), and in human surgical samples of HNSCC WDSCC and PDSCC.

(a) H69

(b) H69

(c) WDSCC

(d) PDSCC